Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone

Blood

Volumn 120, Issue 20, 2012, Pages 4123-4133

  Pamba, Allan ^a   Richardson, Naomi D ^b   Carter, Nick ^a   Duparc, Stephan ^c   Premji, Zul ^d   Tiono, Alfred B ^e   Luzzatto, Lucio ^f  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Magenta Communications Ltd   (United Kingdom)

^c Switzerland   (Switzerland)

^d MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^e Burkina Faso   (Burkina Faso)

^f UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; CHLORPROGUANIL PLUS DAPSONE; DAPSONE;

ARTICLE; BLOOD TRANSFUSION; CHILD; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; GENE MUTATION; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HEMOGLOBIN DETERMINATION; HEMOLYTIC ANEMIA; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MULTICENTER STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL;

EID: 84869816833     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-416032     Document Type: Article

References (51)

1. Luzzatto L. Genetics of red cells and susceptibility to malaria. Blood. 1979;54(5):961-976. (Pubitemid 10197539)
2. Luzzatto L, Notaro R. Malaria. Protecting against bad air. Science. 2001;293(5529):442-443. (Pubitemid 32679060)
3. Motulsky AG. Metabolic polymorphisms and the role of infectious diseases in human evolution. Hum Biol. 1960;32:28-62.
4. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009;42(3):267-278.
5. Saunders MA, Hammer MF, Nachman MW. Nucleotide variability at G6pd and the signature of malarial selection in humans. Genetics. 2002;162(4):1849-1861. (Pubitemid 36114668)
6. Bienzle U, Ayeni O, Lucas AO, Luzzatto L. Glucose-6-phosphate dehydrogenase and malaria. Greater resistance of females heterozygous for enzyme deficiency and of males with nondeficient variant. Lancet. 1972;1(7742):107- 110.
7. Clark TG, Fry AE, Auburn S, et al. Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility. Eur J Hum Genet. 2009;17(8):1080-1085.
8. Guindo A, Fairhurst RM, Doumbo OK,Wellems TE, Diallo DA. X-linked G6PD deficiency protects hemizygous males but not heterozygous females against severe malaria. PLoS Med. 2007;4(3):e66.
9. Luzzatto L. Glucose-6-phosphate dehydrogenase (G6PD) deficiency. In: Warrell D, Cox T, Firth J, eds. Oxford Textbook of Medicine. Vol 3. Oxford, United Kingdom: Oxford University Press; 2010:4473-4480.
10. Luzzatto L, Poggi V. Glucose 6-phosphate dehydrogenase deficiency. In: Orkin S, Nathan D, Ginsburg D, Look T, Fisher D, Lux S, eds. Hematology of Infancy and Childhood. Philadelphia, PA: Saunders; 2009:883-907.
11. Alving AS, Carson PE, Flanagan CL, Ickes CE. Enzymatic deficiency in primaquine-sensitive erythrocytes. Science. 1956;124(3220):484-485.
12. Beutler E. The hemolytic effect of primaquine and related compounds: a review. Blood. 1959;14(2):103-139.
13. BNF Joint Formulary Committee. British National Formulary. London, United Kingdom: Royal Pharmaceutical Society; 2010-2011. http://bnf.org/bnf/bnf/ current/index.htm. Accessed July 1, 2011.
14. Youngster I, Arcavi L, Schechmaster R, et al. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf. 2010;33(9):713-726.
15. Roll Back Malaria. The use of antimalarial drugs: report of an informal consultation. Geneva, Switzerland: World Health Organization; 2001. http://www.rbm.who.int/cmc-upload/0/000/014/923/am-toc.htm#toc. Accessed April 8, 2011.
16. Winstanley P. Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria. Trop Med Int Health. 2001;6(11):952-954. (Pubitemid 33010883)
17. Alloueche A, Bailey W, Barton S, et al. Comparison of chlorproguanil-dapsone with sulfadoxinepyrimethamine for the treatment of uncomplicated falciparum malaria in young African children: double-blind randomised controlled trial. Lancet. 2004;363(9424):1843-1848. (Pubitemid 38748637)
18. World Health Organization. Review of the safety of chlorproguanil-dapsone in the treatment of uncomplicated falciparum malaria in Africa: report of a technical consultation convened by WHO, Geneva, Switzerland, 1-2 July 2004. http://www.who.int/malaria/publications/atoz/who-htm-mal-2005-1106/en/. Accessed May 2, 2011.
19. Luzzatto L. The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics. Lancet. 2010;376(9742):739-741.
20. Ponnampalam JT. Haemoglobinuria after a single dose treatment with dapsone and pyrimethamine for falciparum malaria in a patient with glucose-6-phosphate dehydrogenase deficiency. Trop Geogr Med. 1981;33(4):401-402. (Pubitemid 12105554)
21. Degowin RL, Eppes RB, Powell RD, Carson PE. The haemolytic effects of diaphenylsulfone (DDS) in normal subjects and in those with glucose-6-phosphate- dehydrogenase deficiency. Bull World Health Organ. 1966;35(2):165-179.
22. Premji Z, Umeh RE, Owusu-Agyei S, et al. Chlorproguanil-dapsone- artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria. PLoS One. 2009;4(8):e6682.
23. Tiono AB, Dicko A, Ndububa DA, et al. Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone: a randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria. Am J Trop Med Hyg. 2009;81(6):969-978.
24. Carter N, Pamba A, Duparc S, Waitumbi JN. Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials. Malar J. 2011;10:241.
25. World Health Organization. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria (WHO/HTM/RBM/2003.50). http://whqlibdoc.who.int/hq/2003/WHO-HTM-RBM-2003.50.pdf. Accessed March 27, 2011.
26. Rasheed A, Saeed S, Khan SA. Clinical and laboratory findings in acute malaria caused by various plasmodium species. J Pak Med Assoc. 2009;59(4):220-223.
27. Fischer TM, Meloni T, Pescarmona GP, Arese P. Membrane cross bonding in red cells in favic crisis: a missing link in the mechanism of extravascular haemolysis. Br J Haematol. 1985;59(1):159-169. (Pubitemid 15188831)
28. Vulliamy TJ, Luzzatto L. Glucose-6-phosphate dehydrogenase deficiency and related disorders. In: Handin RI, Lux SE, Stossel TP, eds. Blood: Principles and Practice of Hematology. 2nd Ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2003:1921-1950.
29. Beutler E, Dern RJ, Alving AS. The hemolytic effect of primaquine. IV. The relationship of cell age to hemolysis. J Lab Clin Med. 1954;44(3):439-442.
30. Dern RJ, Beutler E, Alving AS. The hemolytic effect of primaquine. II. The natural course of the hemolytic anemia and the mechanism of its self-limited character. J Lab Clin Med. 1954;44(2):171-176.
31. Beutler E, Kuhl W, Vives-Corrons JL, Prchal JT. Molecular heterogeneity of glucose-6-phosphate dehydrogenase A. Blood. 1989;74(7):2550-2555.
32. World Health Organization. Hemoglobin concentrations for the diagnosis of anemia and assessment of severity. http://www.who.int/vmnis/indicators/ haemoglobin.pdf. Accessed May 15, 2011.
33. Goulart IM, Arbex GL, Carneiro MH, Rodrigues MS, Gadia R. Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlandia [in Portuguese]. Rev Soc Bras Med Trop. 2002;35(5):453-460. (Pubitemid 35439604)
34. Deps PD, Nasser S, Guerra P, Simon M, Birshner Rde C, Rodrigues LC. Adverse effects from multi-drug therapy in leprosy: a Brazilian study. Lepr Rev. 2007;78(3):216-222. (Pubitemid 351171818)
35. Singh H, Nel B, Dey V, Tiwari P, Dulhani N. Adverse effects of multi-drug therapy in leprosy, a two years' experience (2006-2008) in tertiary health care centre in the tribal region of Chhattisgarh state (Bastar, Jagdalpur). Lepr Rev. 2011;82(1):17-24.
36. Gill HJ, Tingle MD, Park BK. N-hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. Br J Clin Pharmacol. 1995;40(6):531-538.
37. Coleman MD, Breckenridge AM, Park BK. Bioactivation of dapsone to a cytotoxic metabolite by human hepatic microsomal enzymes. Br J Clin Pharmacol. 1989;28(4):389-395. (Pubitemid 19269775)
38. Bordin L, Fiore C, Zen F, Coleman MD, Ragazzi E, Clari G. Dapsone hydroxylamine induces premature removal of human erythrocytes by membrane reorganization and antibody binding. Br J Pharmacol. 2010;161(5):1186-1199.
39. Nance WE. Genetic tests with a sex-linked marker: glucose-6-phosphate dehydrogenase. Cold Spring Harb Symp Quant Biol. 1964;29:415-425.
40. Rinaldi A, Filippi G, Siniscalco M. Variability of red cell phenotypes between and within individuals in an unbiased sample of 77 heterozygotes for G6PD deficiency in Sardinia. Am J Hum Genet. 1976;28(5):496-505.
41. Meloni T, Forteleoni G, Dore A, Cutillo S. Favism and hemolytic anemia in glucose-6-phosphate dehydrogenase-deficient subjects in North Sardinia. Acta Haematol. 1983;70(2):83-90. (Pubitemid 13076859)
42. Cui L, Su XZ. Discovery, mechanisms of action and combination therapy of artemisinin. Expert Rev Anti Infect Ther. 2009;7(8):999-1013.
43. Selmeczi K, Robert A, Claparols C, Meunier B. Alkylation of human hemoglobin A0 by the antimalarial drug artemisinin. FEBS Lett. 2004;556(1-3):245-248. (Pubitemid 38058586)
44. Corpolongo A, De Nardo P, Ghirga P, et al. Haemolytic anaemia in an HIV-infected patient with severe falciparum malaria after treatment with oral artemether-lumefantrine. Malar J. 2012;11:91.
45. Jalloh A, Tantular IS, Pusarawati S, et al. Rapid epidemiologic assessment of glucose-6-phosphate dehydrogenase deficiency in malaria-endemic areas in Southeast Asia using a novel diagnostic kit. Trop Med Int Health. 2004;9(5):615-623. (Pubitemid 38657288)
46. Betke K, Brewer G, Kirkman H, et al. Standardization of procedures for the study of glucose-6-phosphate dehydrogenase: report of a WHO Scientific Group. World Health Org Tech Rep Ser. 1967;366:5-53.
47. Salvidio E, Pannacciulli I, Ajmar F, et al. Hemolytic side effects on some antimalarial drugs. Proc Hemlinth Soc Washington. 1972;39:83-100.
48. Odièvre MH, Danekova N, Mesples B, et al. Unsuspected glucose-6-phosphate dehydrogenase deficiency presenting as symptomatic methemoglobinemia with severe hemolysis after fava bean ingestion in a 6-year-old boy. Int J Hematol. 2011;93(5):664-666.
49. Calabrò V, Cascone A, Malaspina P, Battistuzzi G. Glucose-6-phosphate dehydrogenase (G6PD) deficiency in southern Italy: a case of G6PDA(-) associated with favism. Haematologica. 1989;74(1):71-73. (Pubitemid 19088887)
50. Galiano S, Gaetani GF, Barabino A, et al. Favism in the African type of glucose-6-phosphate dehydrogenase deficiency (A-). Br Med J. 1990;300(6719):236. (Pubitemid 20045529)
51. Bain BJ. A ghostly presence-G6PD deficiency. Am J Hematol. 2010;85(4):271.